Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2003

01.08.2003 | Original Article

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

verfasst von: Alexander Drzezga, Nicola Lautenschlager, Hartwig Siebner, Matthias Riemenschneider, Frode Willoch, Satoshi Minoshima, Markus Schwaiger, Alexander Kurz

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2003

Einloggen, um Zugang zu erhalten

Abstract

A high percentage of patients with mild cognitive impairment (MCI) develop clinical dementia of the Alzheimer type (AD) within 1 year. The aim of this longitudinal study was to identify characteristic patterns of cerebral metabolism at baseline in patients converting from MCI to AD, and to evaluate the changes in these patterns over time. Baseline and follow-up examinations after 1 year were performed in 22 MCI patients (12 males, 10 females, aged 69.8±5.8 years); these examinations included neuropsychological testing, structural cranial magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography (PET) evaluation of relative cerebral glucose metabolic rate (rCMRglc). Individual PET scans were stereotactically normalised with NEUROSTAT software (Univ. of Michigan, Ann Arbor, USA). Subsequently, statistical comparison of PET data with an age-matched healthy control population and between patient subgroups was performed using SPM 99 (Wellcome Dept. of Neuroimaging Sciences, London, UK). After 1 year, eight patients (36%) had developed probable AD (referred to as MCIAD), whereas 12 (55%) were still classified as having stable MCI (referred to as MCIMCI). Compared with the healthy control group, a reduced rCMRglc in AD-typical regions, including the temporoparietal and posterior cingulate cortex, was detected at baseline in patients with MCIAD. Abnormalities in the posterior cingulate cortex reached significance even in comparison with the MCIMCI group. After 1 year, MCIAD patients demonstrated an additional bilateral reduction of rCMRglc in prefrontal areas, along with a further progression of the abnormalities in the parietal and posterior cingulate cortex. No such changes were observed in the MCIMCI group. In patients with MCI, characteristic cerebral metabolic differences can be delineated at the time of initial presentation, which helps to define prognostic subgroups. A newly emerging reduction of rCMRglc in prefrontal cortical areas is associated with the transition from MCI to AD.
Literatur
1.
Zurück zum Zitat Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000; 41:1155–1162.PubMed Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000; 41:1155–1162.PubMed
2.
Zurück zum Zitat Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999; 56:303–308.PubMed Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999; 56:303–308.PubMed
3.
Zurück zum Zitat Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12:851–855.PubMed Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12:851–855.PubMed
4.
Zurück zum Zitat Petersen RC. Mild cognitive impairment, and early Alzheimer's disease. The Neurologist 1995; 1:326–344. Petersen RC. Mild cognitive impairment, and early Alzheimer's disease. The Neurologist 1995; 1:326–344.
5.
Zurück zum Zitat Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997; Suppl 1:665–669. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997; Suppl 1:665–669.
6.
Zurück zum Zitat Roman GC, Tatemichi TK, Erkinjunti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250–260.PubMed Roman GC, Tatemichi TK, Erkinjunti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250–260.PubMed
7.
Zurück zum Zitat Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39:1159–1165.PubMed Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39:1159–1165.PubMed
8.
Zurück zum Zitat Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part IV. Rating of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993; 43:2457–2465.PubMed Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part IV. Rating of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993; 43:2457–2465.PubMed
9.
Zurück zum Zitat Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991; 48:278–281.PubMed Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991; 48:278–281.PubMed
10.
Zurück zum Zitat Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994; 44:609–614.PubMed Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994; 44:609–614.PubMed
11.
Zurück zum Zitat Shulman KI, Shedletsky R, Silver IL. The challenge of time: clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1993; 1:135–140. Shulman KI, Shedletsky R, Silver IL. The challenge of time: clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1993; 1:135–140.
12.
Zurück zum Zitat Thalmann B, Monsch AU, Schreittner M, et al. The CERAD neuropsychological assessment battery (CERAD-NAB). A minimal data set as a common tool for German-speaking Europe. Neurobiol Aging 2000; 21:30. Thalmann B, Monsch AU, Schreittner M, et al. The CERAD neuropsychological assessment battery (CERAD-NAB). A minimal data set as a common tool for German-speaking Europe. Neurobiol Aging 2000; 21:30.
13.
Zurück zum Zitat Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr 1983; 17:37–49. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr 1983; 17:37–49.
14.
Zurück zum Zitat Gauggel S, Schmidt A. Was leistet die deutsche Version der Geriatrischen Depressionsskala (GDS)? Geriatrie Praxis 1995; 6:33–36. Gauggel S, Schmidt A. Was leistet die deutsche Version der Geriatrischen Depressionsskala (GDS)? Geriatrie Praxis 1995; 6:33–36.
15.
Zurück zum Zitat McKhann G, Folstein M, Katzmann R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–944.PubMed McKhann G, Folstein M, Katzmann R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–944.PubMed
16.
Zurück zum Zitat Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. Neurology 1998; 51:1546–1554.PubMed Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. Neurology 1998; 51:1546–1554.PubMed
17.
Zurück zum Zitat Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med 1992; 33:1579–1585. Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med 1992; 33:1579–1585.
18.
Zurück zum Zitat Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994; 35:1528–1537.PubMed Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994; 35:1528–1537.PubMed
19.
Zurück zum Zitat Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med 1997; 38:1095–1101.PubMed Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med 1997; 38:1095–1101.PubMed
20.
Zurück zum Zitat Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36:1238–1248.PubMed Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36:1238–1248.PubMed
21.
Zurück zum Zitat Drzezga A, Arnold S, Minoshima S, et al. F-18 FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999; 40:737–746. Drzezga A, Arnold S, Minoshima S, et al. F-18 FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999; 40:737–746.
22.
Zurück zum Zitat Talairach J, Tournoux, P. Co-planar stereotaxic atlas of the human brain. New York: Thieme, 1988. Talairach J, Tournoux, P. Co-planar stereotaxic atlas of the human brain. New York: Thieme, 1988.
23.
Zurück zum Zitat Ishii K, Willoch F, Minoshima S, et al. Statistical brain mapping of18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001; 42:548–557.PubMed Ishii K, Willoch F, Minoshima S, et al. Statistical brain mapping of18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001; 42:548–557.PubMed
24.
Zurück zum Zitat Signorini M, Paulesu E, Friston K, et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 1999; 9:63–80.PubMed Signorini M, Paulesu E, Friston K, et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 1999; 9:63–80.PubMed
25.
Zurück zum Zitat Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 23:6037–6042.CrossRef Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 23:6037–6042.CrossRef
26.
Zurück zum Zitat Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85–94.PubMed Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85–94.PubMed
27.
Zurück zum Zitat Small GW, Leiter F. Neuroimaging for diagnosis of dementia. J Clin Psychiatry 1998; 59 Suppl 11:4–7. Small GW, Leiter F. Neuroimaging for diagnosis of dementia. J Clin Psychiatry 1998; 59 Suppl 11:4–7.
28.
Zurück zum Zitat Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002; 16:515–525.PubMed Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002; 16:515–525.PubMed
29.
Zurück zum Zitat Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001; 49:202–213.CrossRefPubMed Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001; 49:202–213.CrossRefPubMed
30.
Zurück zum Zitat Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179:52–76.CrossRefPubMed Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179:52–76.CrossRefPubMed
31.
Zurück zum Zitat Salat DH, Kaye JA, Janowsky JS. Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease. Arch Neurol 2001; 58:1403–1408.CrossRefPubMed Salat DH, Kaye JA, Janowsky JS. Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease. Arch Neurol 2001; 58:1403–1408.CrossRefPubMed
32.
Zurück zum Zitat Brown DR, Hunter R, Wyper DJ, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. J Psychiatr Res 1996; 30:109–126.PubMed Brown DR, Hunter R, Wyper DJ, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. J Psychiatr Res 1996; 30:109–126.PubMed
33.
Zurück zum Zitat Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm Suppl 1998; 53:237–250.PubMed Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm Suppl 1998; 53:237–250.PubMed
34.
Zurück zum Zitat Fabrigoule C, Rouch I, Taberly A, et al. Cognitive process in preclinical phase of dementia. Brain 1998; 121:135–141.CrossRefPubMed Fabrigoule C, Rouch I, Taberly A, et al. Cognitive process in preclinical phase of dementia. Brain 1998; 121:135–141.CrossRefPubMed
Metadaten
Titel
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
verfasst von
Alexander Drzezga
Nicola Lautenschlager
Hartwig Siebner
Matthias Riemenschneider
Frode Willoch
Satoshi Minoshima
Markus Schwaiger
Alexander Kurz
Publikationsdatum
01.08.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1194-1

Weitere Artikel der Ausgabe 8/2003

European Journal of Nuclear Medicine and Molecular Imaging 8/2003 Zur Ausgabe